Sandoz, the generic pharmaceuticals division of Novartis, is a worldwide leader in generics. Read More.
Report an Adverse Event
The safety of our products and the health and well-being of our patients are our highest priority. If you would like to report an adverse event involving a Sandoz medicine then please click the following link. Read More.
Sandoz registers all trials at www.clinicaltrial.gov.
UK/MKT/SDZ/15-0038, Date of Preparation: June 2016.
Sandoz UK has a portfolio of over 200 products. Our portfolio covers both blockbusters and niche products for all major therapeutic areas, in particular cardiovascular, gastrointestinal, anti-infectives/ antivirals, central nervous system, pain, respiratory and many more. Read More.
Your feedback is valuable as we are committed to continuously improving our products, services and providing greater value to our patients, customers and others. If you have a question or comment that you would like to share with our team, please use the following link. Read More.
Sandoz is the pioneer and a global leader in the rapidly emerging market for biosimilars, also known as follow-on biologics (or biopharmaceuticals). We bring affordable, high-quality biosimilars to patients worldwide, providing greater access to these state-of-the-art treatments. Read More.
At Sandoz, we are always looking for individuals who will share in our commitment to leadership, passion for improving lives and dedication to quality. Read More.
Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines are core to who we are and what we do, our mission is even greater: We endeavour to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.
Sandoz was the first company to develop and market follow-on versions of highly complex biopharmaceuticals. Today, we are a global leader in this segment and have an industry-leading pipeline that will make essential biopharmaceuticals more affordable for all.
As part of the Novartis group, we believe that superior quality is key to our long-term success. Our state-of-the-art technologies, decades of experience, and rigorous across-the-board quality standards all contribute to a product we are justly proud of: quality at an affordable price.